Home › Funds › Mondrian Investment Partners LTD › GSK
Mondrian Investment Partners LTD position in GSK
GSK PLC · Health Care
Mondrian Investment Partners LTD reported holding 4,965,946 shares of GSK (GSK PLC) in its Q3 2026 13F filing — a position valued at US$239.2M, representing 4.44% of its reported portfolio and ranking #5 among its reported holdings. Mondrian Investment Partners LTD has disclosed GSK holdings in 11 of the last 13 reported quarters, going back to Q3 2023.
Last updated: 2026-10-23 · Source: SEC EDGAR Form 13F-HR
How Mondrian Investment Partners LTD's GSK position evolved
Mondrian Investment Partners LTD first disclosed a stake in GSK in Q3 2023 at 1,845,585 shares (US$66.9M). The position peaked in Q4 2025 at 5,806,938 shares, worth US$284.8M. Across 11 filings, Mondrian Investment Partners LTD increased the stake 4 time(s), trimmed it 4 time(s) and left it unchanged 2 time(s). The most recent filing (Q3 2026) shows 4,965,946 shares valued at US$239.2M — an increase of 55,116 shares quarter over quarter.. Notable position changes include a 117% increase in Q4 2023 (shares rose 16% over the following quarter), a 38% increase in Q1 2024 (shares fell 10% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 1.85M | $66.90M | New |
| Q4 2023 | 4.00M | $148.18M | Add |
| Q1 2024 | 5.51M | $236.25M | Add |
| Q3 2024 | 4.96M | $202.94M | Reduce |
| Q4 2024 | 5.84M | $205.92M | Add |
| Q1 2025 | 5.82M | $225.52M | Hold |
| Q3 2025 | 5.84M | $251.94M | Hold |
| Q4 2025 | 5.81M | $284.77M | Reduce |
| Q1 2026 | 4.99M | $275.25M | Reduce |
| Q2 2026 | 4.91M | $257.43M | Reduce |
| Q3 2026 | 4.97M | $239.21M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About GSK and 13F data
GSK (GSK PLC) is a Health Care company. 22 other funds we track also report a position in GSK — the largest reported positions include Dodge & Cox (US$2.53B), DODGE & COX (US$2.53B), PRIMECAP MANAGEMENT CO/CA/ (US$1.32B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding GSK
- Dodge & Cox 48.20M sh · $2.53B · Q2 2026
- DODGE & COX 48.20M sh · $2.53B · Q2 2026
- PRIMECAP MANAGEMENT CO/CA/ 25.18M sh · $1.32B · Q2 2026
- JTC Employer Solutions Trustee Ltd 8.59M sh · $450.31M · Q2 2026
- Grantham, Mayo, Van Otterloo & Co. LLC 3.60M sh · $188.69M · Q2 2026
- EQUITY INVESTMENT CORP 3.27M sh · $171.40M · Q2 2026
More on Mondrian Investment Partners LTD
FAQ
How long has Mondrian Investment Partners LTD held GSK?
Mondrian Investment Partners LTD has disclosed GSK holdings in 11 of the last 13 reported quarters, going back to Q3 2023.
What is Mondrian Investment Partners LTD's current position in GSK?
As of Q3 2026, Mondrian Investment Partners LTD holds 4.97M shares of GSK (GSK PLC), valued at $239.21M, representing 4.44% of its reported portfolio and ranking #5.
Has Mondrian Investment Partners LTD been buying or selling GSK?
In the latest 13F filing (Q3 2026), Mondrian Investment Partners LTD increased its position in GSK. The position peaked in Q4 2025 at 5.81M shares.
Which other funds hold GSK?
Other major institutional holders of GSK include Dodge & Cox, DODGE & COX, PRIMECAP MANAGEMENT CO/CA/, among 22 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.